3 Stocks I Saw on T...
Health Care: Drugs
CytRx Corporation (CYTR: NASDAQ)
$3.58 -0.30 | -7.73%
06/04/12 - 04:00 PM ET
TheStreet Ratings Grade for CYTR
| Buy | Hold | Sell | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A+ | A | A- | B+ | B | B- | C+ | C | C- | D+ | D | D- | E+ | E | E- | F |
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions.
Analyst Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Stong Buy | 3 | 3 | 2 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.00 | 1.00 | 1.00 | 1.00 |
Portfolios with CYTR
- Portfolio NameUser Type
- Uservlady 1
- Contributor5 Stocks Under-$10 Setting ...
- UserHope For The Best
- Userrick epple
- ContributorBarron's Research Reports 1...
- UserNat's
- UserHi Potential
- Usernewintrade Portfolio 1
- Usersteveandvickie Portfolio 1
- Useractive-jrd
Latest CYTR Headlines from TheStreet
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- SeaChange, Tenet: Early Volume Plays 12.03.09 | 08:12 am
- CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests 12.02.09 | 09:12 am
- Correction: CytRx FDA Letter 09.09.09 | 04:09 pm
- CytRx Expects To File FDA Response In 4Q 09.08.09 | 10:09 am
- CytRx Rises On Preclinical Data For Stroke Drug 08.24.09 | 01:08 pm
- Movers Roundup: Massey Energy, MannKind 06.08.09 | 02:06 pm
- CytRx Rises On Analyst's 'Outperform' Rating 06.08.09 | 01:06 pm
- Biotech Notebook: Nastech, Amgen, PDL BioPharma 11.15.07 | 04:11 pm
- Wednesday's Health Winners & Losers 11.14.07 | 03:11 pm
Press Releases for CYTR
- CytRx To Hold Conference Call Today At 10:00 A.m. Eastern Time To Discuss Favorable Results From INNO-206 Clinical Trial In Soft Tissue Sarcoma - Business Wire 06.04.12 | 08:06 am
- CytRx Announces Favorable Results From Phase 1b/2 Clinical Trial With INNO-206 - Business Wire 06.03.12 | 09:06 am
- CytRx Regains NASDAQ Compliance - Business Wire 06.01.12 | 08:06 am
- CytRx Announces The Publication Of INNO-206 Findings In Multiple Myeloma In Clinical Cancer Research - Business Wire 05.29.12 | 08:05 am
- CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer - Business Wire 04.26.12 | 08:04 am
- CytRx Receives NASDAQ Extension - Business Wire 04.23.12 | 08:04 am
- CytRx Announces Issuance Of Key U.S. Patent Covering INNO-206 Linker Technology - Business Wire 04.12.12 | 08:04 am
- CytRx’s INNO-206 To Be Featured In Two Presentations At The American Association For Cancer Research (AACR) 2012 Annual Meeting - Business Wire 03.27.12 | 08:03 am
- CytRx Reports 2011 Financial Results - Business Wire 03.13.12 | 08:03 am
- CytRx To Present At The Roth Capital Partners Annual OC Growth Stock Conference - Business Wire 03.05.12 | 08:03 am
Partner Headlines for CYTR
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- CytRx Is Poised For Growth - Analyst Blog - Zacks 08.13.11 | 12:08 am
- CytRx Reports 2Q 2011 Results - Analyst Blog - Zacks 08.12.11 | 06:08 pm
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- CytRx Completes Sale of Molecular Chaperone Assets - Analyst Blog - Zacks 05.17.11 | 09:05 am
- Company News for April 29, 2011 - Corporate Summary - Zacks 04.29.11 | 10:04 am
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance - NASDAQ 04.28.11 | 04:04 pm
- Mid-Day Update: Stocks Mixed as GDP Data Weighs; Jobless Claims Rise - NASDAQ 04.28.11 | 04:04 pm
- China Analyst: 10 Pharma Stocks With Highest Growth Potential - Seeking Alpha 10.08.10 | 06:10 am
